A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Public ClinicalTrials.gov record NCT04308590. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance (DM/IGT) and/or uncontrolled systolic hypertension (HTN).
Study identification
- NCT ID
- NCT04308590
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 137 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 27, 2020 (Actual)
- Primary completion
- Sep 19, 2024 (Actual)
- Completion
- Sep 19, 2024 (Actual)
- Last update posted
- Sep 4, 2025
2020 – 2024
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 27 | Birmingham | Alabama | 35294 | — |
| Site 17 | Stanford | California | 94305 | — |
| Site 53 | Torrance | California | 90502 | — |
| Site 07 | Atlanta | Georgia | 30318 | — |
| Site 16 | Indianapolis | Indiana | 46202 | — |
| Site 09 | Metairie | Louisiana | 70006 | — |
| Site 36 | Baltimore | Maryland | 21287 | — |
| Site 11 | Fall River | Massachusetts | 02721 | — |
| Site 33 | Rochester | Minnesota | 55905 | — |
| Site 06 | Jackson | Mississippi | 39202 | — |
| Site 54 | Reno | Nevada | 89511 | — |
| Site 10 | Jamaica | New York | 11432 | — |
| Site 44 | New York | New York | 10021 | — |
| Site 01 | Wilmington | North Carolina | 28401 | — |
| Site 30 | Cleveland | Ohio | 44195 | — |
| Site 21 | Columbus | Ohio | 43201-3209 | — |
| Site 02 | Summerville | South Carolina | 29485 | — |
| Site 20 | Dallas | Texas | 75390 | — |
| Site 03 | El Paso | Texas | 79935 | — |
| Site 05 | Fort Worth | Texas | 76132 | — |
| Site 08 | Houston | Texas | 77079 | — |
| Site 15 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04308590, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04308590 live on ClinicalTrials.gov.